{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-001106","form_type":"8-K","ticker":"LFWD","cik":"0001607962","company_name":"Lifeward Ltd.","filed_at":"2026-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.632516+00:00","generated_at":"2026-05-15T09:54:02.312254+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lifeward posts Q4 revenue $5.1M (-33% YoY); enters Oramed deal for oral insulin platform","bullets":["Q4 revenue $5.1M (-33% YoY); full year $22.0M (-14% YoY). ReWalk exoskeleton sales +20% in Q4.","Net loss narrowed 65% to $5.3M ($3.60/share) in Q4; full year $19.9M ($17.16/share).","GAAP gross margin 38.2% in 2025 (non-GAAP 40.9%); operating expenses down 25%.","Cash $2.2M at Dec 31, 2025; expects up to $47M funding from Oramed upon closing strategic deal.","Shareholders approved Oramed deal: Lifeward acquires POD oral insulin tech; Oramed gets up to 49.99% equity."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-001106","json":"https://secwatch.observer/filing/0001178913-26-001106.json","markdown":"https://secwatch.observer/filing/0001178913-26-001106.md","text":"https://secwatch.observer/filing/0001178913-26-001106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607962/000117891326001106/0001178913-26-001106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607962/000117891326001106/zk2634859.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:54:02.312254+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7437613689ff2c622f6e0005bdabfc2e30890ca8","claim":"Lifeward Ltd. reported financial results for the fourth quarter and fiscal year ended December 31, 2025.","evidence_excerpt":"On March 18, 2026, Lifeward Ltd. (the “Company,” “we” or “us”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1607962/000117891326001106/0001178913-26-001106-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}